Enhancing Drug Delivery for Overcoming Angiogenesis and Improving the Phototherapy Efficacy of Glioblastoma by ICG-Loaded Glycolipid-Like Micelles.
Angiogenesis Inhibitors
/ administration & dosage
Animals
Apoptosis
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
Drug Delivery Systems
/ methods
Endothelial Cells
/ drug effects
Glioblastoma
/ pathology
Glycolipids
/ chemistry
Humans
Indocyanine Green
/ administration & dosage
Mice, Nude
Micelles
Nanoparticles
/ administration & dosage
Neovascularization, Pathologic
/ drug therapy
Oligopeptides
/ chemistry
Photosensitizing Agents
/ administration & dosage
Phototherapy
/ methods
Tissue Distribution
Xenograft Model Antitumor Assays
angiogenesis
dual-targeting
glioblastoma
glycolipid-like micelles
phototherapy
Journal
International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
10
2019
accepted:
16
03
2020
entrez:
6
5
2020
pubmed:
6
5
2020
medline:
1
8
2020
Statut:
epublish
Résumé
Phototherapy is a potential new candidate for glioblastoma (GBM) treatment. However inadequate phototherapy due to stability of the photosensitizer and low target specificity induces the proliferation of neovascular endothelial cells for angiogenesis and causes poor prognosis. In this study, we constructed c(RGDfk)-modified glycolipid-like micelles (cRGD-CSOSA) encapsulating indocyanine green (ICG) for dual-targeting neovascular endothelial cells and tumor cells, and cRGD-CSOSA/ICG mediated dual effect of PDT/PTT with NIR irradiation. In vitro, cRGD-CSOSA/ICG inhibited cell proliferation and blocked angiogenesis with NIR irradiation. In vivo, cRGD-CSOSA/ICG exhibited increased accumulation in neovascular endothelial cells and tumor cells. Compared with that of CSOSA, the accumulation of cRGD-CSOSA in tumor tissue was further improved after dual-targeted phototherapy pretreatment. With NIR irradiation, the tumor-inhibition rate of cRGD-CSOSA/ICG was 80.00%, significantly higher than that of ICG (9.08%) and CSOSA/ICG (42.42%). Histological evaluation showed that the tumor vessels were reduced and that the apoptosis of tumor cells increased in the cRGD-CSOSA/ICG group with NIR irradiation. The cRGD-CSOSA/ICG nanoparticle-mediated dual-targeting phototherapy could enhance drug delivery to neovascular endothelial cells and tumor cells for anti-angiogenesis and improve the phototherapy effect of glioblastoma, providing a new strategy for glioblastoma treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Phototherapy is a potential new candidate for glioblastoma (GBM) treatment. However inadequate phototherapy due to stability of the photosensitizer and low target specificity induces the proliferation of neovascular endothelial cells for angiogenesis and causes poor prognosis.
METHODS
METHODS
In this study, we constructed c(RGDfk)-modified glycolipid-like micelles (cRGD-CSOSA) encapsulating indocyanine green (ICG) for dual-targeting neovascular endothelial cells and tumor cells, and cRGD-CSOSA/ICG mediated dual effect of PDT/PTT with NIR irradiation.
RESULTS
RESULTS
In vitro, cRGD-CSOSA/ICG inhibited cell proliferation and blocked angiogenesis with NIR irradiation. In vivo, cRGD-CSOSA/ICG exhibited increased accumulation in neovascular endothelial cells and tumor cells. Compared with that of CSOSA, the accumulation of cRGD-CSOSA in tumor tissue was further improved after dual-targeted phototherapy pretreatment. With NIR irradiation, the tumor-inhibition rate of cRGD-CSOSA/ICG was 80.00%, significantly higher than that of ICG (9.08%) and CSOSA/ICG (42.42%). Histological evaluation showed that the tumor vessels were reduced and that the apoptosis of tumor cells increased in the cRGD-CSOSA/ICG group with NIR irradiation.
CONCLUSION
CONCLUSIONS
The cRGD-CSOSA/ICG nanoparticle-mediated dual-targeting phototherapy could enhance drug delivery to neovascular endothelial cells and tumor cells for anti-angiogenesis and improve the phototherapy effect of glioblastoma, providing a new strategy for glioblastoma treatment.
Identifiants
pubmed: 32368051
doi: 10.2147/IJN.S234240
pii: 234240
pmc: PMC7184138
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Glycolipids
0
Micelles
0
Oligopeptides
0
Photosensitizing Agents
0
arginyl-glycyl-aspartic acid
78VO7F77PN
Indocyanine Green
IX6J1063HV
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2717-2732Informations de copyright
© 2020 Liu et al.
Déclaration de conflit d'intérêts
There are no conflicts of interest to declare in this work.
Références
World Neurosurg. 2018 Jul;115:453-459.e3
pubmed: 29654958
Mol Cancer Ther. 2017 Nov;16(11):2422-2431
pubmed: 28835385
Cancer Res. 2011 Nov 15;71(22):7021-8
pubmed: 21937680
ACS Nano. 2014 Dec 23;8(12):12310-22
pubmed: 25454579
Oncol Lett. 2016 Aug;12(2):1581-1590
pubmed: 27446475
Expert Opin Drug Deliv. 2018 Nov;15(11):1127-1142
pubmed: 30324813
Int J Cancer. 2004 Jul 20;110(6):807-14
pubmed: 15170661
Photodiagnosis Photodyn Ther. 2018 Sep;23:111-118
pubmed: 29894822
Front Biosci (Landmark Ed). 2016 Jun 01;21:1211-21
pubmed: 27100501
J Control Release. 2016 Feb 28;224:217-228
pubmed: 26739551
Br J Cancer. 2000 Jun;82(12):1967-73
pubmed: 10864205
Cancer Res. 2010 Sep 15;70(18):7221-31
pubmed: 20807811
Biomaterials. 2016 Jul;93:10-19
pubmed: 27061266
Wiley Interdiscip Rev Syst Biol Med. 2018 Jan;10(1):
pubmed: 28892308
Cancer Res. 2011 Jun 15;71(12):4055-60
pubmed: 21628493
Biomaterials. 2014 Jul;35(21):5527-38
pubmed: 24731706
Cancer Res. 2008 Jan 15;68(2):516-20
pubmed: 18199547
BMC Cancer. 2006 May 18;6:133
pubmed: 16709245
Colloids Surf B Biointerfaces. 2015 Dec 1;136:402-12
pubmed: 26440756
ACS Appl Mater Interfaces. 2016 Dec 7;8(48):33148-33156
pubmed: 27934140
Biomaterials. 2012 Dec;33(34):8858-67
pubmed: 22959183
Mol Pharm. 2015 Sep 8;12(9):3250-60
pubmed: 26198693
Biomaterials. 2012 Aug;33(22):5603-9
pubmed: 22575835
ACS Appl Mater Interfaces. 2018 Jun 13;10(23):19483-19493
pubmed: 29787247
J Control Release. 2012 Sep 10;162(2):303-9
pubmed: 22759981
Oncotarget. 2016 Nov 8;7(45):72978-72989
pubmed: 27659522
Expert Rev Mol Med. 2008 Aug 07;10:e23
pubmed: 18684337
Endocrinology. 2005 Aug;146(8):3632-41
pubmed: 15845615
Clin Cancer Res. 2005 Jul 1;11(13):4934-40
pubmed: 16000592
Biomaterials. 2017 Nov;144:188-198
pubmed: 28837960
J Control Release. 2015 May 28;206:91-100
pubmed: 25796347
Science. 2018 Mar 23;359(6382):1335-1336
pubmed: 29567696
Colloids Surf B Biointerfaces. 2019 Jan 1;173:581-590
pubmed: 30352379
Mol Pharm. 2012 Jun 4;9(6):1590-8
pubmed: 22497485
Cancer Lett. 2016 Oct 1;380(2):545-51
pubmed: 25527451
Theranostics. 2018 Feb 2;8(5):1227-1242
pubmed: 29507616
Drug Deliv. 2017 Nov;24(1):1843-1855
pubmed: 29182025
Nanomaterials (Basel). 2018 May 19;8(5):
pubmed: 29783745
Chem Commun (Camb). 2006 Nov 13;(42):4398-400
pubmed: 17057856
Int J Nanomedicine. 2012;7:915-24
pubmed: 22412298
Mol Imaging. 2011 Oct;10(5):386-97
pubmed: 21521559
J Neurooncol. 2006 Jul;78(3):281-93
pubmed: 16554966